We are leveraging our innovative Probody™ Platform to discover and develop new cancer immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need, with a primary focus in oncology.

Our innovative Probody Platform is centered on powering the development of two key areas in research and development: cancer immunotherapy and antibody drug conjugates (ADCs). We are pioneering a novel approach to developing ADCs by utilizing our technology to create novel Probody drug conjugates, or PDCs. By widening the therapeutic index of these potent approaches to promising targets, Probody-based therapeutics have the potential to set new standards for safety and efficacy.

At CytomX, programs in our pipeline are directed against two principal areas: novel, promising pathways for which drug development has been significantly limited by broad tissue expression, and clinically and commercially validated targets. Our pipeline, and the pipelines of our partners, includes therapies against important targets for immunotherapy and PDCs that are only addressable utilizing our Probody technology.

Jagged Program
At CytomX, we are working on a novel, first-in-class Probody™ program targeting Jagged ligands in the Notch pathway. Research suggests that the Notch pathway, a developmental signaling pathway, can be reactivated and involved in the carcinogenesis of a number of cancers, including triple negative breast cancer, prostate cancer, pancreatic cancer and multiple myeloma. Recent efforts to target the Notch pathway have been limited by toxicity, such as observed gastrointestinal toxicity with gamma secretase inhibitors. Utilizing our Probody therapeutics platform against Jagged ligands within the Notch pathway represents an important opportunity to widen the therapeutic index and develop meaningful, targeted therapies for Notch-dependent cancers. Our work has also shown that Jagged ligands have potential as Probody drug conjugate targets. We are currently evaluating both the Probody and Probody drug conjugate against the Jagged ligands as potential product candidates for the treatment of cancer.

Cancer Immunotherapy Program
Our increasing understanding of the interaction of tumor cells and the immune system has identified promising new targets for the treatment of cancer. By unleashing the patient’s immune system – predominantly T cells – to kill tumor cells, cancer immunotherapies have the potential to drive potent and durable responses. At CytomX, we are applying the technology to enable the discovery and development of cancer immune therapeutics against a number of promising targets that, with standard antibody approaches, are hampered by on-target toxicities or by enhancement of systemic autoimmunity. This field is advancing very rapidly to combination therapies where tolerability by patients is expected to be a significant challenge. Our Probody technology should expand the therapeutic index for targets that contribute to regulating immunity in healthy tissue and enable realizing the efficacy benefit of cancer immune therapy combinations not otherwise possible.

Probody™ Drug Conjugate Program
The recent approvals of the antibody drug conjugates Kadcyla® and Adcetris® have highlighted the promise of combining extremely potent cytotoxic compounds with the specificity of monoclonal antibodies for the treatment of cancer. However, the target landscape for a conventional antibody-based drug conjugate is limited by toxicity and PK issues for tumor targets that are also expressed significantly in healthy tissue. At CytomX, we are applying our Probody Platform to expand the drug conjugate target landscape and develop Probody drug conjugates (PDCs) to promising targets to treat cancer. PDCs can reduce the collateral damage to normal tissues, maintain long term PK and maximize delivery of toxins to cancerous cells.

KADCYLA is a trademark of Genentech, Inc.  ADCETRIS is a trademark of Seattle Genetics, Inc.